Education Can Improve Phosphate Control
Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.